Table 1.
Clinical and demographic characteristics of infants who received palivizumab versus control infants.
Fig 1.
End-of-season anti-RSV NAb levels in at-risk infants who had received palivizumab prophylaxis in accordance with the BC RSV immunoprophylaxis program guidelines that were in effect during the 2013/14 and 2014/15 seasons (palivizumab group) and in control subjects.
A, Comparison of anti-RSV NAb levels (expressed as neutralizing titers (NT95)) between infants of the palivizumab group and two control groups of infants ≤12 months of age and healthy adults who did not received palivizumab. B, Anti-RSV NAb levels in the palivizumab group plotted against the number of days since they had received the final dose of palivizumab. Dashed lines indicate the median NT95 (grey shaded area indicates min and max value) equivalent to 40 μg/ml palivizumab (defined as the minimum protective threshold). ***, P < 0.001; ****, P < 0.0001; rS, Spearman correlation coefficient.